LA JOLLA, Calif., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTCBB:INNV) today announced that the Company will initiate a nationwide sampling of its topical benzocaine-based premature ejaculation FDA OTC compliant product EjectDelay through the American Urology Association’s (“AUA”) sampling program. Pursuant to the sampling program, each of the approximately 9,000 urologists in the U.S. will be receiving two samples of the product. The Company anticipates the sampling program to be completed within six to eight weeks.
Help employers find you! Check out all the jobs and post your resume.
